AKT1 and diabetic kidney disease: Although the PI3K/Akt is a key signaling pathway for QDTS in the treatment of DN through network pharmacology and experimental verification, it needs further experiment to confirm that QDTS reduces podocyte damage in diabetic nephropathy by targeting AKT1 and JUN, such as gene intervention.